Drugs / CRTE7A2-01 TCR-T Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05122221 | Jul 2022 → Mar 2023 | anus cancer, cervical cancer, head and neck cancer | Corregene Biotechnology Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRTE7A2-01 TCR-T Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05122221 ↗ |
| Modality | Cell therapy | “TCR-T cells” NCT05122221 ↗ |
| Route | Intravenous | “the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.” NCT05122221 ↗ |